|
Author
|
Year
|
Study Design
|
SJS/TEN Casesa
(n)
|
Controls
|
Data Collection
|
Specific Requirement for Case Allopurinol-Exposureb
|
Matching Criteria
|
NOS
|
|---|
| | | | |
Matched
(n)
|
Population
(n)
|
SJS/TEN Cases
|
Controls
| | | |
|---|
|
Hung SI [10]
|
2005
|
Case-control
|
21
|
135
|
93c
|
R
|
R
|
Yes
|
Drug, hospital
|
7
|
|
Kaniwa N [11]
|
2008
|
Case-population controld
|
10
|
-
|
493e
|
R
|
-
|
NR
|
-
|
3
|
|
Lonjou C [12]
|
2008
|
Case-population controld
|
31
|
-
|
1822f
|
R (N = 70), P (N = 80)
|
-
|
Yes
|
-
|
3
|
|
Tassaneeyakul W [13]
|
2009
|
Case-controlg
|
27
|
54
|
-
|
R
|
R
|
Yes
|
Drug, hospital
|
7
|
|
Kang HR [14]
|
2011
|
Case-control
|
5
|
57
|
485h
|
R
|
R
|
Yes
|
Drug, hospital
|
4
|
|
Jung JW [15]
|
2011
|
Retrospective cohort
|
2
|
432
|
485h
|
R
|
R
|
Yes
|
Drug, hospital
|
6
|
- Abbreviation: R = retrospective, P = prospective, NOS = Newcastle-Ottawa Scale, NR = not report
-
a Only patients that received drugs of interest (Allopurinol) were included.
-
b Including: maximum time to develop adverse drug reaction (ADR) from drug initiation [10, 12, 13], improvement of symptom upon drug discontinuation [10, 13], and exclusion of patients without symptoms upon re-exposure [10].
-
c Healthy subjects randomly selected from a biobank under nationwide population study, in which 3312 Han Chinese descendants were recruited based on the geographic distribution across Taiwan. There was no self-report of adverse drug events by any of the population control.
-
d Using population based as control group.
-
e Data of healthy Japanese reported by Tanaka H, et al. [20].
-
f Using allele frequencies from European populations available on dbMHC: http://www.ncbi.nlm.nih.gov/projects/mhc/ihwg.cgi
-
g Author described the study as cross-sectional case-control study.
-
h Using allele frequency from the general population of Korea.
